Up-front inotuzumab and blinatumomab trials
| Trial . | Planned patients . | Ages . | Intervention . | Status . | Clinical trials . |
|---|---|---|---|---|---|
| Inotuzumab | |||||
| COG AALL1732 | 4772 | 1-25 | 2 cycles of Ino in consolidation | Recruiting | NCT03959085 |
| ALLIANCE A041501 | 310 | 18-39 | 2 cycles of Ino in consolidation | Suspended | NCT03150693 |
| ALLTogether | 6430 | 0-45 | 2 cycles of Ino prior to maintenance | Recruiting | NCT04307576 |
| GRAALL (B-2022) | 600 | 18-65 | 1 cycle of Ino in delayed intensification | Planned | Pending9 |
| Blinatumomab | |||||
| Jiangsu Institute of Hematology | 35 | 15-59 | Reduced-intensity induction + blina | Recruiting | NCT05557110 |
| HOVON146ALL | 71 | 18-70 | Steroid + blina prephase; blina for 2 cycles in consolidation | Closed to accrual | NCT03541083 |
| Blina-CELL (CZECRIN) | 45 | 18-65 | 1 cycle of blina + chemo for induction | Closed to accrual | NCT04554485 |
| GIMEMA (LAL2317) | 149 | 18-65 | 2 cycles of blina added to chemo | Closed to accrual | NCT03367299 |
| GRAALL (B/2014-QUEST) | 95 | 18-59 | 5 cycles of blina added to consolidation/ maintenance for MRD+ | Closed to accrual | NCT03709719 |
| GMALL (MolAct-1) | 84 | 18+ | Up to 2 cycles of blina added to chemo | Completed, results pending | NCT03109093 |
| Inotzumab + blinatumomab | |||||
| MDACC | 80 | 14+ | Blina cycles 5-8 + Ino in cycles 6 and 8 | Recruiting | NCT02877303 |
| Trial . | Planned patients . | Ages . | Intervention . | Status . | Clinical trials . |
|---|---|---|---|---|---|
| Inotuzumab | |||||
| COG AALL1732 | 4772 | 1-25 | 2 cycles of Ino in consolidation | Recruiting | NCT03959085 |
| ALLIANCE A041501 | 310 | 18-39 | 2 cycles of Ino in consolidation | Suspended | NCT03150693 |
| ALLTogether | 6430 | 0-45 | 2 cycles of Ino prior to maintenance | Recruiting | NCT04307576 |
| GRAALL (B-2022) | 600 | 18-65 | 1 cycle of Ino in delayed intensification | Planned | Pending9 |
| Blinatumomab | |||||
| Jiangsu Institute of Hematology | 35 | 15-59 | Reduced-intensity induction + blina | Recruiting | NCT05557110 |
| HOVON146ALL | 71 | 18-70 | Steroid + blina prephase; blina for 2 cycles in consolidation | Closed to accrual | NCT03541083 |
| Blina-CELL (CZECRIN) | 45 | 18-65 | 1 cycle of blina + chemo for induction | Closed to accrual | NCT04554485 |
| GIMEMA (LAL2317) | 149 | 18-65 | 2 cycles of blina added to chemo | Closed to accrual | NCT03367299 |
| GRAALL (B/2014-QUEST) | 95 | 18-59 | 5 cycles of blina added to consolidation/ maintenance for MRD+ | Closed to accrual | NCT03709719 |
| GMALL (MolAct-1) | 84 | 18+ | Up to 2 cycles of blina added to chemo | Completed, results pending | NCT03109093 |
| Inotzumab + blinatumomab | |||||
| MDACC | 80 | 14+ | Blina cycles 5-8 + Ino in cycles 6 and 8 | Recruiting | NCT02877303 |
Blina, blinatumomab; Ino, inotuzumab; MRD+, MRD-positive.